Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), sold 303 shares at $2.36 ($746) on 2023-04-30, disclosed to the SEC on 2023-07-06.
Open-market sale of $746 RSLS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.60 | 109 | $283 | 38.0% |
| 2 | $2.36 | 96 | $227 | 30.4% |
| 3 | $2.41 | 98 | $236 | 31.7% |
| Total | $2.46 avg | 303 | $746 | 100% |
| Filing → |
| RSLS | SELL | 2023-07-19 | $156 | — | Filing → |
| RSLS | SELL | 2023-03-07 | $4K | — | Filing → |
| RSLS | SELL | 2022-12-20 | $125K | — | Filing → |